India, Oct. 23 -- Avacta Therapeutics (AVCT.L) announced new preclinical data for AVA6103, its investigational FAP-activated exatecan peptide-drug conjugate, demonstrating antitumor activity in HER2-positive, FAP-positive gastric tumors that had progressed following treatment with Enhertu.
In preclinical studies, all animals treated with AVA6103 in an early-stage tumor model achieved partial responses, with tumor growth inhibition more than twice that observed with Enhertu.
In animals with larger established tumors, AVA6103 inhibited tumor growth and achieved partial responses, while Enhertu demonstrated limited activity. Animals that had previously progressed on Enhertu achieved stable disease with AVA6103, whereas those retreated with E...